Vaxcyte, Inc. $PCVX Shares Purchased by Baird Financial Group Inc.

Baird Financial Group Inc. boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 21.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,299 shares of the company’s stock after purchasing an additional 2,523 shares during the quarter. Baird Financial Group Inc.’s holdings in Vaxcyte were worth $540,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Vaxcyte by 0.7% in the first quarter. Vanguard Group Inc. now owns 12,043,805 shares of the company’s stock worth $454,774,000 after purchasing an additional 82,118 shares during the period. Wellington Management Group LLP boosted its holdings in Vaxcyte by 44.4% in the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock worth $242,303,000 after purchasing an additional 1,972,918 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in Vaxcyte by 57.3% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company’s stock worth $116,469,000 after purchasing an additional 518,255 shares during the period. Invesco Ltd. boosted its holdings in Vaxcyte by 7.7% in the first quarter. Invesco Ltd. now owns 1,255,827 shares of the company’s stock worth $47,420,000 after purchasing an additional 89,773 shares during the period. Finally, Woodline Partners LP boosted its holdings in Vaxcyte by 1.5% in the fourth quarter. Woodline Partners LP now owns 1,120,922 shares of the company’s stock worth $91,759,000 after purchasing an additional 16,977 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cowen reissued a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $121.75.

Vaxcyte Stock Down 2.2%

PCVX stock opened at $32.00 on Thursday. The company has a market capitalization of $4.15 billion, a P/E ratio of -7.79 and a beta of 1.04. The company has a 50-day simple moving average of $33.19 and a 200 day simple moving average of $39.94. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period last year, the business earned ($1.10) EPS. Equities analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.